Friday, 16 October 2026European Markets

FOUNTAIN Stock Over 24% Up In The Last 10 Sessions

Loading stream...

Fountain S.A. of Belgium experienced a stunning 24% gain within 10 trading sessions from EUR1 to EUR1.24, including two consecutive days of gains. Meanwhile, its index BEL 20 dropped 0.43% due to three successive trading days with losses for this stock.

Fountain's Performance Against Market Downturn

Fountain's stock price rise stands out against a general market downturn. Yet investors should proceed with caution; its trailing twelve month EPS (Earnings Per Share) stands at EUR-0.15, suggesting a lack of profitability over recent time.

Stochastic Oscillator Analysis

Analysis using a stochastic oscillator indicates that this stock may be oversold. This tool helps detect whether an asset may be overbought (potentially overvalued) or oversold (potentially undervalued).

Volatility of Fountain Stocks

Volatility, which measures an expected price range for stocks, has fluctuated considerably for Fountain. Their intraday variation averages were 1.39% last week, 1.32% last month and 7.53% last quarter; their highest average amplitude of volatility peaked at 1.96% last week, 4.75% last month and 7.53% last quarter.

Potential Risks and Gains

Given these factors, investors should carefully weigh the potential gains from Fountain's recent price growth against any risks posed by its negative EPS and high degree of stock volatility.

More news about FOUNTAIN (FOU.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com